Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.
First, Walgreens is rolling out a hybrid pharmacist model designed to expand flexibility and clinical impact across its workforce. The new structure blends traditional in-store pharmacy work with centralized and remote clinical responsibilities, allowing pharmacists to split time between patient-facing services and hub-based operational or clinical tasks. The goal is to ease staffing pressures while extending pharmacist involvement in medication therapy management and broader clinical support.
Next, according to a study in the Journal of the American Pharmacists Association, pharmacies are continuing to solidify their role as critical access points for immunizations and injectable medications. With expanding scope of practice and high geographic reach, community pharmacies are increasingly delivering routine vaccines and administering injectables that would otherwise require clinic or physician office visits. This shift is helping to reduce barriers to preventive care and chronic disease management, particularly in underserved or high-demand settings.
In commercial news, GoodRx and Eli Lilly partnered to expand access pathways for the newlyapproved Foundayo oral GLP-1, as well as the Zepbound KwikPen,through broader pharmacy network availability and cash-pay affordability programs. The collaboration is aimed at improving patient access outside traditional insurance coverage by offering these products on GoodRx’s site, reflecting continued momentum toward direct-to-consumer and cash-pay models in high-demand metabolic therapies.
Next, a multi-billion-dollar radiopharmaceutical collaboration between Regeneron and Telix underscores accelerating investment in precision cancer therapies. Radiopharmaceuticals deliver targeted radioactive compounds directly to cancer cells, enabling highly localized treatment with reduced systemic exposure. The scale of recent deals in this space highlights growing confidence in radioligand and targeted radiation therapies as a key pillar of next-generation oncology pipelines.
Finally, AbbVie has entered into an exclusive licensing agreement with Haisco valued at up to approximately $745 million. The deal grants AbbVie exclusive rights to develop, manufacture, and commercialize assets from Haisco’s pipeline outside Greater China. Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in development, regulatory, and commercial milestone payments, along with tiered royalties on future sales.
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.
